Bupropion - an antidepressant drug with broad therapeutic potential
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.070Keywords
bupropion, depression, smoking cessation, obesity, ADHDAbstract
Introduction: Bupropion is currently mainly used as an atypical antidepressant due to its psychotropic effects. In addition, it shows high potential in reducing withdrawal cravings in addicts, which is also used in the treatment of nicotinism. However, studies in recent years have shown that it may also be useful in other conditions.
Aim of the study: Our aim was to review the known usage of bupropion in the fields of psychiatry, neurology and internal medicine, and to identify potential directions for further research.
Methods and materials: We reviewed the literature available in the PubMed database, using the key words: "bupropion"; "depression"; "smoking cessation"; "obesity"; "ADHD".
Results: Bupropion- an antidepressant drug belonging to the group of selective norepinephrine and dopamine reuptake inhibitors. Bupropion is approved by the FDA(Food and Drug Administration) for the treatment of depression, seasonal affective disorder and nicotinism. The literature shows that it is also effective in off-label indications - treatment of antidepressant-induced sexual dysfunction, attention deficit hyperactivity disorder (ADHD), depression in bipolar disorder, obesity, neuropathic pain and cancer-related fatigue syndrome.
Conclusion: Due to the specific effects of bupropion, there are many more usage for the drug than the primary indications for which it is usually used. The usage of the drug described in the literature require additional studies on a larger group of patients.
References
Huecker MR, Smiley A, Saadabadi A. Bupropion. 2022 May 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 29262173.
Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3(1):45-53. doi: 10.2147/copd.s1121. PMID: 18488428; PMCID: PMC2528204.
Cahill K, Stevens S, Perera R et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013 May 31;2013(5):CD009329. doi: 10.1002/14651858.CD009329.pub2. PMID: 23728690; PMCID: PMC8406789.
Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021 Jan 14;384(2):140-153. doi: 10.1056/NEJMoa2020214. PMID: 33497547; PMCID: PMC8111570.
Patel K, Allen S, Haque MN et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016 Apr;6(2):99-144. doi: 10.1177/2045125316629071. Epub 2016 Feb 18. PMID: 27141292; PMCID: PMC4837968.
Hendrick V, Suri R, Gitlin MJ, et al. Bupropion Use During Pregnancy: A Systematic Review. Prim Care Companion CNS Disord. 2017 Sep 21;19(5):17r02160. doi: 10.4088/PCC.17r02160. PMID: 28973846.
Berigan TR. The Many Uses of Bupropion and Bupropion Sustained Release (SR) in Adults. Prim Care Companion J Clin Psychiatry. 2002 Feb;4(1):30-32. doi: 10.4088/pcc.v04n0110a. PMID: 15014734; PMCID: PMC314381.
Verbeeck W, Bekkering GE, Van den Noortgate W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017 Oct 2;10(10):CD009504. doi: 10.1002/14651858.CD009504.pub2. PMID: 28965364; PMCID: PMC6485546.
Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014 Jun;84:1-11. doi: 10.1016/j.phrs.2014.04.004. Epub 2014 Apr 19. PMID: 24754973.
Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43. doi: 10.1002/oby.20309. PMID: 23408728; PMCID: PMC3739931.
Candler T, Kühnen P, Prentice AM et al. Epigenetic regulation of POMC; implications for nutritional programming, obesity and metabolic disease. Front Neuroendocrinol. 2019 Jul;54:100773. doi: 10.1016/j.yfrne.2019.100773. Epub 2019 Jul 22. PMID: 31344387.
Onakpoya IJ, Lee JJ, Mahtani KR et al. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020 Apr;86(4):646-667. doi: 10.1111/bcp.14210. Epub 2020 Feb 4. PMID: 31918448; PMCID: PMC7098870.
Halseth A, Shan K, Gilder K et al. Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion. Obes Sci Pract. 2018 Feb 23;4(2):141-152. doi: 10.1002/osp4.156. PMID: 29670752; PMCID: PMC5893468.
Salehifar E, Azimi S, Janbabai G et al. Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. BMC Cancer. 2020 Feb 27;20(1):158. doi: 10.1186/s12885-020-6618-9. PMID: 32106832; PMCID: PMC7045731.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Sebastian Bróż, Sara Dankiewicz, Przemysław Żelazny, Joanna Filipczak, Aleksandra Swora, Joanna Borowik, Oliwer Sygacz, Wojciech Brodowski, Piotr Pawłowski, Katarzyna Basta-Arciszewska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 1691
Number of citations: 0